{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,21]],"date-time":"2023-05-21T04:31:22Z","timestamp":1684643482048},"reference-count":4,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cancer"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1038\/s41568-019-0206-9","type":"journal-article","created":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T13:02:32Z","timestamp":1569934952000},"page":"603-604","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["When the cancer researcher becomes the patient"],"prefix":"10.1038","volume":"19","author":[{"given":"Cynthia A.","family":"Zahnow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,1]]},"reference":[{"key":"206_CR1","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1128\/MCB.9.3.1165","volume":"9","author":"RM Hudziak","year":"1989","unstructured":"Hudziak, R. M. et al. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell Biol. 9, 1165\u20131172 (1989).","journal-title":"Mol. Cell Biol."},{"issue":"Suppl. 12","key":"206_CR2","first-page":"89","volume":"26","author":"MD Pegram","year":"1999","unstructured":"Pegram, M. D. & Slamon, D. J. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. Semin. Oncol. 26 (Suppl. 12), 89\u201395 (1999).","journal-title":"Semin. Oncol."},{"key":"206_CR3","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon, D. et al. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 365, 1273\u20131283 (2011).","journal-title":"N. Engl. J. Med."},{"key":"206_CR4","unstructured":"US National Library of Medicine. ClinicalTrials.gov, \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01101438\n                    \n                   (2019)."}],"container-title":["Nature Reviews Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41568-019-0206-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41568-019-0206-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41568-019-0206-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T22:20:05Z","timestamp":1684621205000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41568-019-0206-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,1]]},"references-count":4,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["206"],"URL":"https:\/\/doi.org\/10.1038\/s41568-019-0206-9","relation":{},"ISSN":["1474-175X","1474-1768"],"issn-type":[{"value":"1474-175X","type":"print"},{"value":"1474-1768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,1]]},"assertion":[{"value":"1 October 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}